adxs-503,pembrolizumab
advaxis,merck
['sclc', 'lcsm,(-blcsm)', 'adxs-503', 'lung', 'nsclc', 'award', 'pembro']
dr. aaron lisberg, recipient of 2019 cda award from lungevity, presents a poster about using adxs-503 immunotherapy to overcome resistance to pembro #asco22 #lcsm #nsclc 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.